Clinical trials: Locoregional Neoplasm Recurrence
Breast Cancer Recurrent
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
POLAR is a phase III clinical trial, which will test the safety and efficacy of an investigational combination of drugs to learn whether the combination of drugs works for a specific cancer.
- Trial name
- POLAR (NCT03820830)
- Testing
- Palbociclib 125mg, Standard endocrine therapy
- Where
- 53 sites in Austria, France and 4 more
- Volunteers
- 405 people
- Sponsor
- ETOP IBCSG Partners Foundation
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00004223
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 76 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
R115777 in Treating Patients With Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have advanced bladder…
- Trial name
- NCT00006376
- Testing
- chemotherapy, tipifarnib
- Where
- 2 sites in United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Colorectal Neoplasms
Locally Advanced Colorectal Cancer and Local Recurrences in Västra Götaland
The aim of this study is to review the treatment strategies of locally advanced colorectal cancer and locally recurrent rectal cancer in Västra Götaland during 1995-2016.
- Trial name
- NCT04406974
- Testing
- Surgery or treatment for local recurrence, Surgery for advanced colorectal cancer
- Where
- Sweden
- Volunteers
- 4,000 people
- Sponsor
- Sahlgrenska University Hospital
B Cell Lymphoma, T Cell Lymphoma
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
The primary objective of this study is to evaluate the safety of intratumoral Polyinosinicpolycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC)(Hiltonol®) in addition to low-dose local radiotherapy…
- Trial name
- NCT00880867
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Nevada Cancer Institute
Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer
This phase I trial investigates the best dose and side effects of NBTXR3 when given together with radiation therapy for the treatment of non-small cell lung cancer that cannot be treated by surgery (inoperable) and has come back…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8
- Trial name
- NCT04505267
- Testing
- Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms
Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
The goal of this randomized Phase II clinical trial is to test the effects of omitting chest wall radiotherapy (RT) after prosthetic reconstruction in early-stage breast cancer patients.
- Trial name
- NCT06464913
- Testing
- With or without chest wall RT
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer, Colorectal Neoplasms
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I
- Trial name
- T1CR (NCT06314971)
- Testing
- Tw1CE
- Where
- 3 sites in United States, Japan and 1 more
- Volunteers
- 138 people
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma
Bipolar RFA Using Twin ICW Electrodes vs. Switching Monopolar RFA for Recurrent HCC
This study was conducted to provide preliminary data for the main trial to compare efficacy between bipolar radiofrequency ablation (RFA) using twin internally cooled-wet electrodes and switching monopolar RFA using separable…
- Trial name
- NCT03806218
- Testing
- Bipolar RFA, SM-RFA, Twin internally cooled-wet electrodes
- Where
- South Korea
- Volunteers
- 77 people
- Sponsor
- Seoul National University Hospital
Locoregional Recurrence, Breast Cancer
Postoperative Re-irradiaTion With and Without HYPERthermia, or Surgery Only: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast Cancer
In the Netherlands, breast cancer patients with locoregional recurrence (LRR) and intermediate- and high-risk factors are treated with surgery with or without postoperative re-irradiation with or without hyperthermia.
- Conditions
- Locoregional Recurrence, Breast Cancer, Re-irradiation, Hyperthermia
- Trial name
- RT-HYPE (NCT06452485)
- Testing
- No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups.
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Amsterdam UMC, location VUmc
Melanoma
WoW - Single- vs Two-staged Excisions of Thin Melanoma
The overall aim of this national, multicenter, prospective, randomized, and controlled study is to enhance the management of patients with thin melanoma (≤1 mm Breslow thickness).
- Trial name
- WoW (NCT06363591)
- Testing
- Surgery, No Surgery
- Where
- Sweden
- Volunteers
- 2,486 people
- Sponsor
- Vastra Gotaland Region
Neuroblastoma
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00072358
- Testing
- anti-GD2 murine IgG3 monoclonal antibody 3F8
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Lung Cancer (NSCLC)
Multimodal CT-Based Risk Stratification for Postoperative Local Recurrence in NSCLC: A Multicenter Study
This multicenter retrospective study is designed to develop and validate a CT-based multimodal risk stratification approach for postoperative local recurrence after curative-intent resection of non-small cell lung cancer (NSCLC).
- Trial name
- NCT07552532
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Guangming Lu
Brain Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability…
- Conditions
- Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm
- Trial name
- NCT00054795
- Testing
- Motexafin Gadolinium
- Where
- 92 sites in United States, Australia and 6 more
- Volunteers
- 550 people
- Sponsor
- Pharmacyclics LLC.
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
This Phase I clinical trial evaluates the safety, tolerability, and optimal dosing of Zanzalintinib in combination with Pembrolizumab and Cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head…
- Conditions
- Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis
- Trial name
- NCT06912087
- Testing
- Zanzalintinib, Cetuximab, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
This randomized phase III trial compares two different high-dose chemotherapy regimens followed by a stem cell transplant in treating younger patients with high-risk neuroblastoma.
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT00567567
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin
- Where
- 190 sites in United States, Australia and 4 more
- Volunteers
- 665 people
- Sponsor
- Children's Oncology Group
Melanoma
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
This study will evaluate the clinical and pathological response to vemurafenib and cobimetinib in the neoadjuvant treatment of patients with histologically confirmed, BRAF V600 mutation-positive Stage IIIB and C melanoma.
- Trial name
- NCT02036086
- Testing
- Vemurafenib, Cobimetinib
- Where
- 3 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer, Early Breast Cancer
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who…
- Trial name
- CAMBRIA-1 (NCT05774951)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 709 sites in United States, Argentina and 37 more
- Volunteers
- 4,300 people
- Sponsor
- AstraZeneca